Safety and antimicrobial efficacy of CSL787, a novel nebulized IgG therapy, in patients with bronchiectasis: results from a randomized phase 1 trial

2026/04/07 by D.G. Downey, Ilka Schulze, Andreas Eich +6 · 1 voice
Medicine · #Asthma and respiratory diseases #Cystic Fibrosis Research Advances #Respiratory and Cough-Related Research

paper · doi:10.1093/ajrccm/aamag135

openalex publication_date 2026/04/07 · openalex created_date 2026/04/12 · openalex updated_date 2026/08/01

Abstract

Damian G Downey, M.D, Ilka Schulze, M.D., Ph.D, Andreas Eich, M.D, Dave Singh, M.D, Michael Larbig, M.D., Ph.D, Oliver Vit, Laurent B Nicolas, Ph.D, Sanjay

Discussions

• Safety and antimicrobial efficacy of CSL787, a novel nebulized IgG therapy, in patients with bronchiectasis: results from a randomized phase 1 trial Inhaled immunoglobulin is safe in bronchiectasis an [bsky, 0 points, 0 comments]

Related

• Treatable traits in bronchiectasis
• A new anti-inflammatory treatment for bronchiectasis: a viewpoint on optimal dose selection for DPP1 inhibition in clinical practice
• Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: the GOLD science committee report 2019
• Utility of bronchoalveolar lavage in checkpoint inhibitor pneumonitis evaluation: a narrative review
• EUFOREA consensus on biologics for CRSwNP with or without asthma